Literature DB >> 28535714

Non-muscle-invasive bladder cancer: a vision for the future.

Per-Uno Malmström1, Sachin Agrawal2, Mats Bläckberg3, Peter J Boström4, Bernard Malavaud5, Dirk Zaak6, Gregers G Hermann7.   

Abstract

The management of non-muscle-invasive bladder cancer (NMIBC) has evolved from the first reports on bladder endoscopy and transurethral resection to the introduction of adjuvant intravesical treatment. However, disease recurrence and progression remain an ongoing risk, placing a heavy burden on healthcare resources and on patients' quality of life. Deeper understanding of the molecular basis of the disease and developments in optics, lasers and computer science are already offering opportunities to revolutionize care and improve long-term prognosis. This article discusses developments likely to cause a paradigm shift towards the delivery of personalized care and reduced burden of disease in NMIBC.

Entities:  

Keywords:  Biomarkers; bladder cancer; cost effectiveness; diagnosis; flexible cystoscopy; laser; medicotechnology

Mesh：

Year:  2017        PMID： 28535714     DOI： 10.1080/21681805.2017.1283359

Source DB:  PubMed          Journal:  Scand J Urol        ISSN： 2168-1805            Impact factor:   1.612


  13 in total

Review 1.  [Current and established diagnostic modalities for bladder cancer].

Authors:  D Zaak; C Ohlmann; A Stenzl
Journal:  Urologe A       Date:  2018-06       Impact factor: 0.639

2.  Matrix Metalloproteinase 11 is a Potential Biomarker in Bladder Cancer Diagnosis and Prognosis.

Authors:  Chen Chen; Xiaoping Liu; Jiazhi Jiang; Shenjuan Li; Gang Wang; Lingao Ju; Fubing Wang; Tongzu Liu; Sheng Li
Journal:  Onco Targets Ther       Date:  2020-09-11       Impact factor: 4.147

3.  Identification of Biomarkers Correlated with the TNM Staging and Overall Survival of Patients with Bladder Cancer.

Authors:  Sheng Li; Xiaoping Liu; Tongzu Liu; Xiangyu Meng; Xiaohong Yin; Cheng Fang; Di Huang; Yue Cao; Hong Weng; Xiantao Zeng; Xinghuan Wang
Journal:  Front Physiol       Date:  2017-11-28       Impact factor: 4.566

4.  CCL2 Expression in Tumor Cells and Tumor-Infiltrating Immune Cells Shows Divergent Prognostic Potential for Bladder Cancer Patients Depending on Lymph Node Stage.

Authors:  Markus Eckstein; Elena Epple; Rudolf Jung; Katrin Weigelt; Verena Lieb; Danijel Sikic; Robert Stöhr; Carol Geppert; Veronika Weyerer; Simone Bertz; Astrid Kehlen; Arndt Hartmann; Bernd Wullich; Helge Taubert; Sven Wach
Journal:  Cancers (Basel)       Date:  2020-05-15       Impact factor: 6.639

5.  Piwi-like 1 and -2 protein expression levels are prognostic factors for muscle invasive urothelial bladder cancer patients.

Authors:  Markus Eckstein; Rudolf Jung; Katrin Weigelt; Danijel Sikic; Robert Stöhr; Carol Geppert; Abbas Agaimy; Verena Lieb; Arndt Hartmann; Bernd Wullich; Sven Wach; Helge Taubert
Journal:  Sci Rep       Date:  2018-12-06       Impact factor: 4.379

6.  Bladder tissue characterization using probe-based Raman spectroscopy: Evaluation of tissue heterogeneity and influence on the model prediction.

Authors:  Eliana Cordero; Jan Rüger; Dominik Marti; Abdullah S Mondol; Thomas Hasselager; Karin Mogensen; Gregers G Hermann; Jürgen Popp; Iwan W Schie
Journal:  J Biophotonics       Date:  2019-12-02       Impact factor: 3.207

7.  The inhibitory effect of silencing CDCA3 on migration and proliferation in bladder urothelial carcinoma.

Authors:  Dexin Shen; Yayun Fang; Fenfang Zhou; Zhao Deng; Kaiyu Qian; Gang Wang; Yu Xiao; Lingao Ju; Xinghuan Wang
Journal:  Cancer Cell Int       Date:  2021-05-12       Impact factor: 5.722

Review 8.  Non-Muscular Invasive Bladder Cancer: Re-envisioning Therapeutic Journey from Traditional to Regenerative Interventions.

Authors:  Kuan-Wei Shih; Wei-Chieh Chen; Ching-Hsin Chang; Ting-En Tai; Jeng-Cheng Wu; Andy C Huang; Ming-Che Liu
Journal:  Aging Dis       Date:  2021-06-01       Impact factor: 6.745

9.  Oridonin Promotes Apoptosis and Restrains the Viability and Migration of Bladder Cancer by Impeding TRPM7 Expression via the ERK and AKT Signaling Pathways.

Authors:  Xianping Che; Jiangtao Zhan; Fan Zhao; Zunhe Zhong; Mianchuan Chen; Ruifa Han; Yi Wang
Journal:  Biomed Res Int       Date:  2021-07-05       Impact factor: 3.411

10.  MINDY1 promotes bladder cancer progression by stabilizing YAP.

Authors:  Yongwen Luo; Jun Zhou; Jianing Tang; Fengfang Zhou; Zhiwen He; Tongzu Liu; Tao Liu
Journal:  Cancer Cell Int       Date:  2021-07-27       Impact factor: 5.722
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.